Story perspectives

Moderna and Merck’s mRNA vaccine hits Phase 3 endpoints

8/20/2026

Summary

Story summary

Moderna and Merck announced their personalized mRNA vaccine intismeran met primary and secondary Phase 3 endpoints.
The INTerpath-001 trial enrolled 1,137 high-risk melanoma patients who had surgery.
Combination with Merck’s Keytruda significantly extended recurrence-free survival compared with Keytruda alone.
Moderna’s shares surged up to 177% intraday, its biggest single-day gain since 2018.
Barclays projects the therapy could generate about $3 billion in annual melanoma sales by 2035.

1 of 1

Story summary

Moderna and Merck announced their personalized mRNA vaccine intismeran met primary and secondary Phase 3 endpoints.
The INTerpath-001 trial enrolled 1,137 high-risk melanoma patients who had surgery.
Combination with Merck’s Keytruda significantly extended recurrence-free survival compared with Keytruda alone.
Moderna’s shares surged up to 177% intraday, its biggest single-day gain since 2018.
Barclays projects the therapy could generate about $3 billion in annual melanoma sales by 2035.